Invention Grant
- Patent Title: Combination of pimavanserin and risperidone for the treatment of psychosis
- Patent Title (中): 帕米芬汀和利培酮组合用于治疗精神病
-
Application No.: US13754769Application Date: 2013-01-30
-
Publication No.: US09050343B2Publication Date: 2015-06-09
- Inventor: Perry Peters , David Furlano , Daun Bahr , Daniel Van Kammen , Mark Brann
- Applicant: Perry Peters , David Furlano , Daun Bahr , Daniel Van Kammen
- Applicant Address: US CA San Diego
- Assignee: ACADIA Pharmaceuticals Inc.
- Current Assignee: ACADIA Pharmaceuticals Inc.
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K31/4468 ; A61K31/45 ; A61K31/00 ; A61K31/4515 ; A61K31/5513 ; A61K31/554

Abstract:
Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.
Public/Granted literature
- US20130143901A1 COMBINATION OF PIMAVANSERIN AND RISPERIDONE FOR THE TREATMENT OF PSYCHOSIS Public/Granted day:2013-06-06
Information query
IPC分类: